Zscaler: The Best Value In Cybersecurity Already Got Its Re-Rating

Zscaler is rated HOLD after a recent share-price surge removed the prior risk/reward asymmetry, despite strong business momentum and sector-leading value metrics. Weak FY27 net new ARR guidance is seen as limiting upside until management demonstrates renewed growth or raises its outlook. AI-related seat-based pricing exposure and competitive threats remain key risks behind Zscaler’s valuation discount to CrowdStrike and Palo Alto.

Analysis

The key risk is not simply slower growth: if net-new ARR fails to reaccelerate, investors may lower the growth multiple before reported revenue fully reflects the deceleration. That makes ZS vulnerable to a second leg of valuation compression after its recent rerating, even if current operating momentum remains healthy. The near-term catalyst is management’s next quarterly update and any evidence that bookings or large-deal conversion are tracking above the FY27 trajectory; absent that, upside likely requires an explicit guide revision.

AI creates a two-sided effect. If customers move from seat-based licenses toward agent- or usage-based deployment, ZS could face pricing pressure; conversely, more automated workloads may increase demand for security and partially offset seat dilution. The deciding evidence is renewal pricing, net retention, and ARR contribution by product—not broad AI adoption claims. CRWD and PANW could gain in competitive displacements, but their own exposure to packaging and AI-driven security competition argues against treating them as clean hedges.

The contrarian risk is that the market overweights seat erosion and underweights expanding security workloads, making ZS’s valuation discount an opportunity if ARR stabilizes. Over 1–3 months, guidance and renewal data matter most; over 6–18 months, realized pricing and product mix determine whether AI is a net demand tailwind or a monetization headwind. Falsify the cautious view with an upward ARR guide revision and improving net retention; strengthen it with guide cuts or weaker renewal economics.

Key Decisions for Investors

• Avoid chasing ZS after the rerating; keep exposure modest until ARR trajectory and renewal economics provide confirmation. The supplied data do not establish a valuation floor or justify a price target.
• For a relative-value expression, consider a small short ZS versus a dollar-neutral basket of CRWD and PANW only if ZS underperforms on the next guidance or renewal datapoint. Treat this as a relative-growth thesis, not a claim that the peers are insulated from AI pricing risk.
• Review or exit the relative short if ZS raises FY27 net-new ARR guidance or shows improving net retention and renewal pricing; reassess rather than add if CRWD or PANW weaken on comparable indicators.
• Track product-level ARR, renewal discounting, seat-versus-usage pricing mix, and large-deal conversion. Until these are disclosed or independently evidenced, treat AI-related seat erosion and workload expansion as competing hypotheses, not established impacts.